AJANTA PHARMA
|
AJANTA PHARMA Last 5 Year Balance Sheet History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
EQUITY AND LIABILITIES | |||||
Share Capital | ₹25 Cr | ₹17 Cr | ₹17 Cr | ₹18 Cr | ₹18 Cr |
Equity - Authorised | ₹30 Cr | ₹30 Cr | ₹30 Cr | ₹30 Cr | ₹30 Cr |
Equity - Issued | ₹25 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr |
Equity Paid Up | ₹25 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr |
Equity Shares Forfeited | ₹0.09 Cr | ₹0.09 Cr | ₹0.09 Cr | ₹0.09 Cr | ₹0.09 Cr |
Adjustments to Equity | - | - | - | - | - |
Preference Capital Paid Up | - | - | - | - | - |
Face Value | ₹2.00 | ₹2.00 | ₹2.00 | ₹2.00 | ₹2.00 |
Share Warrants & Outstandings | ₹0.34 Cr | ₹0.30 Cr | ₹0.54 Cr | ₹0.47 Cr | ₹1.10 Cr |
Total Reserves | ₹3,362 Cr | ₹3,247 Cr | ₹2,978 Cr | ₹2,581 Cr | ₹2,227 Cr |
Securities Premium | - | - | - | ₹1.06 Cr | - |
Capital Reserves | - | - | - | - | - |
Profit & Loss Account Balance | ₹3,141 Cr | ₹2,718 Cr | ₹2,156 Cr | ₹1,617 Cr | ₹1,270 Cr |
General Reserves | ₹211 Cr | ₹532 Cr | ₹817 Cr | ₹951 Cr | ₹951 Cr |
Other Reserves | ₹10 Cr | ₹-2.60 Cr | ₹5.14 Cr | ₹11 Cr | ₹5.88 Cr |
Reserve excluding Revaluation Reserve | ₹3,362 Cr | ₹3,247 Cr | ₹2,978 Cr | ₹2,581 Cr | ₹2,227 Cr |
Revaluation reserve | - | - | - | - | - |
Shareholder's Funds | ₹3,388 Cr | ₹3,264 Cr | ₹2,996 Cr | ₹2,599 Cr | ₹2,245 Cr |
Minority Interest | - | - | - | - | - |
Long-Term Borrowings | - | - | - | - | - |
Secured Loans | ₹1.25 Cr | ₹1.64 Cr | ₹1.60 Cr | ₹0.74 Cr | ₹0.66 Cr |
Non Convertible Debentures | - | - | - | - | - |
Converible Debentures & Bonds | - | - | - | - | - |
Packing Credit - Bank | - | - | - | - | - |
Inter Corporate & Security Deposit | - | - | - | - | - |
Term Loans - Banks | - | - | - | - | - |
Term Loans - Institutions | - | - | - | - | - |
Other Secured | ₹1.25 Cr | ₹1.64 Cr | ₹1.60 Cr | ₹0.74 Cr | ₹0.66 Cr |
Unsecured Loans | - | - | - | - | - |
Fixed Deposits - Public | - | - | - | - | - |
Loans and advances from subsidiaries | - | - | - | - | - |
Inter Corporate Deposits (Unsecured) | - | - | - | - | - |
Foreign Currency Convertible Notes | - | - | - | - | - |
Long Term Loan in Foreign Currency | - | - | - | - | - |
Loans - Banks | - | - | - | - | - |
Loans - Govt. | - | - | - | - | - |
Loans - Others | - | - | - | - | - |
Other Unsecured Loan | - | - | - | - | - |
Deferred Tax Assets / Liabilities | ₹0.95 Cr | ₹46 Cr | ₹42 Cr | ₹56 Cr | ₹27 Cr |
Deferred Tax Assets | ₹131 Cr | ₹84 Cr | ₹60 Cr | ₹36 Cr | ₹63 Cr |
Deferred Tax Liability | ₹132 Cr | ₹130 Cr | ₹102 Cr | ₹91 Cr | ₹90 Cr |
Other Long Term Liabilities | ₹29 Cr | ₹21 Cr | ₹23 Cr | ₹16 Cr | ₹0.33 Cr |
Long Term Trade Payables | - | - | - | - | - |
Long Term Provisions | ₹147 Cr | ₹216 Cr | ₹208 Cr | ₹155 Cr | ₹134 Cr |
Total Non-Current Liabilities | ₹177 Cr | ₹285 Cr | ₹275 Cr | ₹228 Cr | ₹162 Cr |
Current Liabilities | - | - | - | - | - |
Trade Payables | ₹423 Cr | ₹327 Cr | ₹374 Cr | ₹362 Cr | ₹225 Cr |
Sundry Creditors | ₹423 Cr | ₹327 Cr | ₹374 Cr | ₹362 Cr | ₹225 Cr |
Acceptances | - | - | - | - | - |
Due to Subsidiaries- Trade Payables | - | - | - | - | - |
Other Current Liabilities | ₹669 Cr | ₹301 Cr | ₹214 Cr | ₹180 Cr | ₹111 Cr |
Bank Overdraft / Short term credit | ₹3.84 Cr | ₹9.49 Cr | ₹6.39 Cr | ₹3.66 Cr | ₹18 Cr |
Advances received from customers | ₹10 Cr | ₹52 Cr | ₹21 Cr | ₹15 Cr | ₹4.36 Cr |
Interest Accrued But Not Due | - | - | - | - | - |
Share Application Money | - | - | - | - | - |
Current maturity of Debentures & Bonds | - | - | - | - | - |
Current maturity - Others | - | - | - | - | - |
Other Liabilities | ₹656 Cr | ₹240 Cr | ₹187 Cr | ₹161 Cr | ₹89 Cr |
Short Term Borrowings | - | - | - | ₹43 Cr | ₹33 Cr |
Secured ST Loans repayable on Demands | - | - | - | ₹43 Cr | ₹33 Cr |
Working Capital Loans- Sec | - | - | - | ₹43 Cr | ₹33 Cr |
Buyers Credits - Unsec | - | - | - | - | - |
Commercial Borrowings- Unsec | - | - | - | - | - |
Other Unsecured Loans | - | - | - | ₹-43 Cr | ₹-33 Cr |
Short Term Provisions | ₹47 Cr | ₹19 Cr | ₹251 Cr | ₹160 Cr | ₹128 Cr |
Proposed Equity Dividend | - | - | - | - | - |
Provision for Corporate Dividend Tax | - | - | - | - | - |
Provision for Tax | ₹33 Cr | ₹7.94 Cr | ₹239 Cr | ₹151 Cr | ₹121 Cr |
Provision for post retirement benefits | - | - | - | - | - |
Preference Dividend | - | - | - | - | - |
Other Provisions | ₹14 Cr | ₹11 Cr | ₹12 Cr | ₹9.16 Cr | ₹7.67 Cr |
Total Current Liabilities | ₹1,139 Cr | ₹647 Cr | ₹839 Cr | ₹746 Cr | ₹498 Cr |
Total Liabilities | ₹4,705 Cr | ₹4,197 Cr | ₹4,109 Cr | ₹3,572 Cr | ₹2,906 Cr |
ASSETS | |||||
Gross Block | ₹2,283 Cr | ₹2,207 Cr | ₹2,141 Cr | ₹1,976 Cr | ₹1,579 Cr |
Less: Accumulated Depreciation | ₹786 Cr | ₹703 Cr | ₹600 Cr | ₹504 Cr | ₹411 Cr |
Less: Impairment of Assets | - | - | - | - | - |
Net Block | ₹1,496 Cr | ₹1,504 Cr | ₹1,541 Cr | ₹1,472 Cr | ₹1,168 Cr |
Lease Adjustment A/c | - | - | - | - | - |
Capital Work in Progress | ₹209 Cr | ₹153 Cr | ₹108 Cr | ₹132 Cr | ₹262 Cr |
Non Current Investments | ₹25 Cr | ₹25 Cr | - | ₹12 Cr | ₹23 Cr |
Long Term Investment | ₹25 Cr | ₹25 Cr | - | ₹12 Cr | ₹23 Cr |
Quoted | - | - | - | - | - |
Unquoted | ₹25 Cr | ₹25 Cr | - | ₹12 Cr | ₹30 Cr |
Long Term Loans & Advances | ₹135 Cr | ₹236 Cr | ₹231 Cr | ₹164 Cr | ₹148 Cr |
Other Non Current Assets | ₹4.85 Cr | ₹5.88 Cr | ₹11 Cr | ₹10 Cr | ₹4.08 Cr |
Total Non-Current Assets | ₹1,871 Cr | ₹1,932 Cr | ₹1,891 Cr | ₹1,791 Cr | ₹1,605 Cr |
Current Assets Loans & Advances | - | - | - | - | - |
Currents Investments | ₹510 Cr | ₹122 Cr | ₹176 Cr | ₹67 Cr | ₹65 Cr |
Quoted | ₹386 Cr | ₹122 Cr | ₹139 Cr | ₹15 Cr | ₹37 Cr |
Unquoted | ₹124 Cr | - | ₹37 Cr | ₹52 Cr | ₹28 Cr |
Inventories | ₹816 Cr | ₹791 Cr | ₹766 Cr | ₹496 Cr | ₹436 Cr |
Raw Materials | ₹264 Cr | ₹240 Cr | ₹291 Cr | ₹175 Cr | ₹151 Cr |
Work-in Progress | ₹52 Cr | ₹47 Cr | ₹48 Cr | ₹41 Cr | ₹36 Cr |
Finished Goods | ₹189 Cr | ₹180 Cr | ₹146 Cr | ₹102 Cr | ₹102 Cr |
Packing Materials | ₹52 Cr | ₹49 Cr | ₹58 Cr | ₹48 Cr | ₹43 Cr |
Stores Ā and Spare | - | - | - | - | - |
Other Inventory | ₹258 Cr | ₹275 Cr | ₹223 Cr | ₹129 Cr | ₹104 Cr |
Sundry Debtors | ₹1,057 Cr | ₹1,020 Cr | ₹738 Cr | ₹775 Cr | ₹459 Cr |
Debtors more than Six months | ₹27 Cr | ₹21 Cr | ₹10 Cr | ₹11 Cr | ₹4.28 Cr |
Debtors Others | ₹1,041 Cr | ₹1,014 Cr | ₹742 Cr | ₹777 Cr | ₹460 Cr |
Cash and Bank | ₹331 Cr | ₹212 Cr | ₹210 Cr | ₹205 Cr | ₹101 Cr |
Cash in hand | ₹0.01 Cr | ₹0.03 Cr | ₹0.03 Cr | ₹0.03 Cr | ₹0.05 Cr |
Balances at Bank | ₹331 Cr | ₹212 Cr | ₹210 Cr | ₹205 Cr | ₹100 Cr |
Other cash and bank balances | - | - | - | - | - |
Other Current Assets | ₹22 Cr | ₹35 Cr | ₹104 Cr | ₹69 Cr | ₹97 Cr |
Interest accrued on Investments | ₹2.48 Cr | ₹0.58 Cr | ₹1.76 Cr | ₹0.35 Cr | ₹0.32 Cr |
Interest accrued on Debentures | - | - | - | - | - |
Deposits with Government | - | - | - | - | - |
Interest accrued and or due on loans | - | - | - | - | - |
Prepaid Expenses | ₹16 Cr | ₹16 Cr | ₹14 Cr | ₹22 Cr | ₹12 Cr |
Other current_assets | ₹3.17 Cr | ₹19 Cr | ₹89 Cr | ₹46 Cr | ₹85 Cr |
Short Term Loans and Advances | ₹89 Cr | ₹85 Cr | ₹223 Cr | ₹169 Cr | ₹143 Cr |
Advances recoverable in cash or in kind | ₹47 Cr | ₹39 Cr | ₹31 Cr | ₹28 Cr | ₹21 Cr |
Advance income tax and TDS | - | - | ₹190 Cr | ₹139 Cr | ₹121 Cr |
Amounts due from directors | - | - | - | - | - |
Due From Subsidiaries | - | - | - | - | - |
Inter corporate deposits | - | - | - | - | - |
Corporate Deposits | - | - | - | - | - |
Other Loans & Advances | ₹42 Cr | ₹47 Cr | ₹2.55 Cr | ₹1.35 Cr | ₹1.69 Cr |
Total Current Assets | ₹2,825 Cr | ₹2,264 Cr | ₹2,218 Cr | ₹1,781 Cr | ₹1,301 Cr |
Net Current Assets (Including Current Investments) | ₹1,686 Cr | ₹1,617 Cr | ₹1,379 Cr | ₹1,036 Cr | ₹802 Cr |
Miscellaneous Expenses not written off | - | - | - | - | - |
Total Assets | ₹4,705 Cr | ₹4,197 Cr | ₹4,109 Cr | ₹3,572 Cr | ₹2,906 Cr |
Contingent Liabilities | ₹4.03 Cr | ₹6.76 Cr | ₹82 Cr | ₹49 Cr | ₹46 Cr |
Total Debt | ₹1.43 Cr | ₹1.91 Cr | ₹1.69 Cr | ₹46 Cr | ₹36 Cr |
Book Value | 269.07 | 382.20 | 346.24 | 297.80 | 257.19 |
Adjusted Book Value | 269.07 | 254.80 | 230.83 | 198.53 | 171.46 |
Compare Balance Sheet of peers of AJANTA PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
AJANTA PHARMA | ₹29,800.5 Cr | 6% | 9.2% | 88.2% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹365,071.0 Cr | 0.2% | -6.1% | 55.7% | Stock Analytics | |
CIPLA | ₹111,808.0 Cr | -2.5% | -5.1% | 48.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹104,300.0 Cr | -0.9% | 5% | 19.2% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹101,202.0 Cr | 1.8% | 2.2% | 88.6% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹101,035.0 Cr | -3.7% | -1.4% | 26% | Stock Analytics |
AJANTA PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
AJANTA PHARMA | 6% |
9.2% |
88.2% |
SENSEX | -1.4% |
-0.6% |
20.1% |
You may also like the below Video Courses